ClinicalTrials.gg
CompletedNCT04418466DLP-114Updated Dec 27, 2024Results posted

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

A Phase 1/2 interventional study of Risperidone in Schizophrenia, sponsored by Delpor, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Delpor, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
99th of 123
34 · median 100
Started
2021
with 3 others
Phase 1/2
3 of 127
none open now
Registered
119th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 99th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2021, is one of 3 in phase 1/2, and was the 119th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).

Read the detailed description

Phase 1 open-label study in stable schizophrenia patients designed to evaluate the safety, tolerability, and Pharmacokinetics of switching from 2 mg/day or 3 mg/day oral risperidone to two DLP-114 devices for a six or twelve-month dosing period.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • risperidone
  • schizophrenia
  • implant
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients 18-70 years of age of both sexes diagnosed with schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual (DSM)-V who have been stable on oral risperidone (2mg-3mg) for at least 2 weeks.
  2. Patient (and/or a patient's authorized legal representative) has provided written
  3. Patient meets the following criteria:

    1. Outpatient status
    2. PANSS Total Score ≤ 80 at screening.
    3. A score of ≤ 4 on the following PANSS items:

    i. Conceptual disorganization ii. Suspiciousness iii. Hallucinatory behavior iv. Unusual thought content v. Hostility d. Clinical Global Impression Scale (CGI-S) ≤ 4 (moderately ill)\Lack of suicidal ideation or behavior; Columbia Suicide Severity Rating Scale (C-SSRS) score type of 4-5 require evaluation by mental health professional to ensure patient safety in study

  4. (BMI) within the range of 18.5 to 40.0 kg/m2 (inclusive);
  5. Ability to understand the nature and objectives of the trial, including risks and adverse events, and be able to read, review and sign the informed consent document prior to conduct of any study procedures;
  6. Willing and able to comply with the requirements of the study protocol; including willingness to visit the clinical facility for all outpatient visits and confinement periods;
  7. Have suitable venous access for blood sampling.
  8. Patient is assessed by the Investigator to be symptomatically stable with regard to pre-existing medical conditions as evidenced by medical history, non-clinically significant findings on physical examination, vital signs, clinical laboratory evaluations (hematology, serum chemistries, and urinalysis) or 12-lead (ECG). Subjects may continue on their current prescribed medication regimens to control pre-existing medical and psychiatric conditions (other than schizophrenia) including the use of prescribed PRN medications.

Exclusion criteria

Exclusion Criteria:

  1. PANSS score at baseline is ≥ 20% change from screening.
  2. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator
  3. Patient has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide.
  4. Patient experiencing acute depressive symptoms within the past 30 days, according to the Investigator's opinion, that required treatment with an antidepressant
  5. Has a current or recent (within 12 months) diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.
  6. Have impaired hepatic ( (ALT) /aspartate aminotransferase (AST) >1.5 times higher than the ) or renal function (\<50 mL/min)
  7. Previously defined to Risperidone
  8. History of neuroleptic malignant syndrome (NMS)
  9. Electroconvulsive therapy within 6 months of admission
  10. Requires current use of agents that are strong inhibitors and inducers of cytochrome P450;
  11. Known hypersensitivity or allergy to lidocaine or any local anesthetic agent of the amide type (local anesthetic used during implant and explant procedures);
  12. Presence of skin disorders (such as, but not limited to, skin cancer, psoriasis, eczema, or atopic dermatitis), evidence of recent sunburn, scar tissue, tattoo, open sore, body piercing or branding at the intended implantation site that would interfere with the implantation procedure or interfere with implant site assessments as determined by the investigator;
  13. History of clinically significant hypersensitivity or allergic reactions;
  14. Known allergy or hypersensitivity to para-aminobenzoic acid (PABA);
  15. Known allergy or hypersensitivity to parabens, local anesthetics of the ester type, and sulfa drugs including antibiotics and thiazide diuretics;
  16. Known hypersensitivity to titanium, implant materials or procedure;
  17. Administration of an drug or device within 1 month prior to first dosing;
  18. Positive result for surface antigen (HBsAg), (HCV) antibody, or antibody;
  19. Pregnant or lactating patients. Positive pregnancy test;
  20. Positive drug test for Methamphetamines, Opiates, Cocaine, Phencyclidine, Benzodiazepines, Barbiturates, Methadone, Antidepressants and Amphetamines or positive alcohol test at screening or prior to first dose;
  21. Poor CYP2D6 metabolizer;
  22. History of skin picking or delusional parasitosis;
  23. Known history of abnormal scar formation or family history of keloid formation
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    DLP-114 alpha-4 (6-months)

    Group 1: 6-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (360mg of Risperidone per implant) for 6 months

    Combination Product: Risperidone

  • Experimental
    DLP-114 alpha-7 (12-months)

    Group 2: 12-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (435mg of Risperidone per implant) for 12 months

    Combination Product: Risperidone

Interventions

  • Combination productRisperidone

    Risperidone Implant

    Also known as: DLP-114

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of Participants with Treatment-Emergent Adverse Events.

    Time frame: Up to 8 months and up to 15 months for groups 1 and 2 respectively.

  2. Percentage of Implant Site Assessments With a Dermal Irritation Scale Rating Greater Than Zero

    Evaluate the incidence of local site reactions. Percentage of implant site assessments with a dermal irritation scale rating greater than zero (rating scale is 0 to 4, where 0 indicates no erythema or edema, and 4 indicates erythema or slight eschar).

    Time frame: 6 months and 12 months for groups 1 and 2 respectively.

  3. Number of Participants Who Experienced an AE Related to Implantation or Explantation Procedures

    Number of participants who experienced an Adverse Events related to Implantation or Explantation Procedures

    Time frame: 6 months and 12 months for groups 1 and 2 respectively.

Secondary outcomes

  1. Oral Phase Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During 24 Hours After 3 Days of Repeated 3mg QD Oral Administrations

    Oral Phase Cave: Average plasma concentration of active moiety (risperidone + 9 OH risperidone) during 24 hours after 3 days of repeated 3mg QD oral administrations

    Time frame: t=0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours following oral administration.

  2. Implant Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During the Implant Phase

    Average plasma concentration of active moiety (risperidone + 9 OH risperidone) following switch from oral risperidone to subcutaneous implantation of two DLP-114 devices at specific time intervals per protocol for 6 months or 12 months (groups 1 and 2 respectively).

    Time frame: PK blood draw & analysis were performed per protocol time intervals; 0, 1, 2, 3, 4, 6, 8, 12, 24, 28, 32, 36, 48, and 52 hours post-placement of implants; 1x/day for 4 additional days, 1x/week during days 5-28; biweekly until day of device removal.

  3. Average Positive and Negative Syndrome Scale (PANSS) During the Study (Oral & Implant Phases)

    Average Positive and Negative Syndrome Scale (PANSS) during the study (Oral \& Implant Phases). The average PANSS score was calculated for each participant during the study. The PANSS score reported is the average of all participants who completed the study in each group. The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology)

    Time frame: For group 1: Screening period, day -1, day 84, day 183; and for Group 2: Screening period, day -1, day 84, day 182, day 280, day 364.

  4. Average Clinical Global Impression-Improvement (CGI-I) Scale During the Implant Phase

    Average Clinical Global Impression-Improvement (CGI-I) Scale during the Implant Phase. The average CGI-I score was calculated for each participant during the Implant Phase. The CGI-I score reported is the average of all participants who completed the study in each group. The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

    Time frame: CGI-I assessments were conducted over the course of the study per the protocol schedule of assessments. For Group 1: day 7, 14, 28, 42, 70, 112,140, 68, 183 and for Group 2: day 7, 14, 28, 56, 84, 112,140, 168,182, 210, 238, 252, 280, 308, 336, 350, 364.

  5. Average Daily Risperidone Implant Output During the Implant Phase

    Average daily Risperidone Implant output during the Implant Phase. Average daily output is calculated by using the amount of Risperidone drug substance remaining in the DLP-114 reservoir following removal. The average daily output is calculated for each participant by using the two devices that each participant received. Risperidone output reported as the average for each group.

    Time frame: 6-months and 12-months for groups 1 and 2 respectively. Remaining Risperidone measurements taken at the end of the Implant Phase.

  6. Implant Device Placement Depth

    Average depth of implant device placement measured by ultrasound in mm. The average depth was calculated for each participant. The implant device depth reported is the average of all participants who completed the study in each group.

    Time frame: Group 1 (6-month): Ultrasound on days 14 and 183. Group 2 (12-month): Ultrasound on days 14 and 364.

  7. Number of Participants Who Experienced Implant Migration in at Least One of the Implanted Devices

    Implant migration is defined as a distance of greater than 3cm between the initial incision and the proximal end of the implant device prior to removal.

    Time frame: Group 1 (6-month): Assessments performed day 1 and day 183. Group 2 (12-month): Assessments performed day 1 and 364.

07

Results

Posted Dec 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Started1717
Started implant phase1414
Completed1211
Not completed56

Outcome measures

PrimaryAdverse Events

Number of Participants with Treatment-Emergent Adverse Events.

Time frame:
Up to 8 months and up to 15 months for groups 1 and 2 respectively.
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Adverse Events1013
PrimaryPercentage of Implant Site Assessments With a Dermal Irritation Scale Rating Greater Than Zero

Evaluate the incidence of local site reactions. Percentage of implant site assessments with a dermal irritation scale rating greater than zero (rating scale is 0 to 4, where 0 indicates no erythema or edema, and 4 indicates erythema or slight eschar).

Time frame:
6 months and 12 months for groups 1 and 2 respectively.
Reported as:
Number · percentage of site assessments rated >0
Percentage of Implant Site Assessments With a Dermal Irritation Scale Rating Greater Than Zero
percentage of site assessments rated >0DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Percentage of Implant Site Assessments With a Dermal Irritation Scale Rating Greater Than Zero10.15.1
PrimaryNumber of Participants Who Experienced an AE Related to Implantation or Explantation Procedures

Number of participants who experienced an Adverse Events related to Implantation or Explantation Procedures

Time frame:
6 months and 12 months for groups 1 and 2 respectively.
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an AE Related to Implantation or Explantation Procedures
ParticipantsDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Number of Participants Who Experienced an AE Related to Implantation or Explantation Procedures72
SecondaryOral Phase Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During 24 Hours After 3 Days of Repeated 3mg QD Oral Administrations

Oral Phase Cave: Average plasma concentration of active moiety (risperidone + 9 OH risperidone) during 24 hours after 3 days of repeated 3mg QD oral administrations

Time frame:
t=0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours following oral administration.
Reported as:
Mean · ng/mL
Oral Phase Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During 24 Hours After 3 Days of Repeated 3mg QD Oral Administrations
ng/mLDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Oral Phase Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During 24 Hours After 3 Days of Repeated 3mg QD Oral Administrations43.07 ± 13.3243.86 ± 14.12
SecondaryImplant Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During the Implant Phase

Average plasma concentration of active moiety (risperidone + 9 OH risperidone) following switch from oral risperidone to subcutaneous implantation of two DLP-114 devices at specific time intervals per protocol for 6 months or 12 months (groups 1 and 2 respectively).

Time frame:
PK blood draw & analysis were performed per protocol time intervals; 0, 1, 2, 3, 4, 6, 8, 12, 24, 28, 32, 36, 48, and 52 hours post-placement of implants; 1x/day for 4 additional days, 1x/week during days 5-28; biweekly until day of device removal.
Reported as:
Mean · ng/ML
Implant Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During the Implant Phase
ng/MLDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Implant Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During the Implant Phase11.54 ± 3.9914.41 ± 6.76
SecondaryAverage Positive and Negative Syndrome Scale (PANSS) During the Study (Oral & Implant Phases)

Average Positive and Negative Syndrome Scale (PANSS) during the study (Oral \& Implant Phases). The average PANSS score was calculated for each participant during the study. The PANSS score reported is the average of all participants who completed the study in each group. The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology)

Time frame:
For group 1: Screening period, day -1, day 84, day 183; and for Group 2: Screening period, day -1, day 84, day 182, day 280, day 364.
Reported as:
Mean · Total score on PANSS scale
Average Positive and Negative Syndrome Scale (PANSS) During the Study (Oral & Implant Phases)
Total score on PANSS scaleDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Average Positive and Negative Syndrome Scale (PANSS) During the Study (Oral & Implant Phases)56.92 ± 7.5557.51 ± 8.43
SecondaryAverage Clinical Global Impression-Improvement (CGI-I) Scale During the Implant Phase

Average Clinical Global Impression-Improvement (CGI-I) Scale during the Implant Phase. The average CGI-I score was calculated for each participant during the Implant Phase. The CGI-I score reported is the average of all participants who completed the study in each group. The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

Time frame:
CGI-I assessments were conducted over the course of the study per the protocol schedule of assessments. For Group 1: day 7, 14, 28, 42, 70, 112,140, 68, 183 and for Group 2: day 7, 14, 28, 56, 84, 112,140, 168,182, 210, 238, 252, 280, 308, 336, 350, 364.
Reported as:
Mean · Score on CGI-I scale
Average Clinical Global Impression-Improvement (CGI-I) Scale During the Implant Phase
Score on CGI-I scaleDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Average Clinical Global Impression-Improvement (CGI-I) Scale During the Implant Phase3.5 (1 to 5)3.7 (1 to 5)
SecondaryAverage Daily Risperidone Implant Output During the Implant Phase

Average daily Risperidone Implant output during the Implant Phase. Average daily output is calculated by using the amount of Risperidone drug substance remaining in the DLP-114 reservoir following removal. The average daily output is calculated for each participant by using the two devices that each participant received. Risperidone output reported as the average for each group.

Time frame:
6-months and 12-months for groups 1 and 2 respectively. Remaining Risperidone measurements taken at the end of the Implant Phase.
Reported as:
Mean · mg/day
Average Daily Risperidone Implant Output During the Implant Phase
mg/dayDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Average Daily Risperidone Implant Output During the Implant Phase0.676 ± 0.1560.531 ± 0.106
SecondaryImplant Device Placement Depth

Average depth of implant device placement measured by ultrasound in mm. The average depth was calculated for each participant. The implant device depth reported is the average of all participants who completed the study in each group.

Time frame:
Group 1 (6-month): Ultrasound on days 14 and 183. Group 2 (12-month): Ultrasound on days 14 and 364.
Reported as:
Mean · mm
Implant Device Placement Depth
mmDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Implant Device Placement Depth4.10 ± 1.844.85 ± 1.40
SecondaryNumber of Participants Who Experienced Implant Migration in at Least One of the Implanted Devices

Implant migration is defined as a distance of greater than 3cm between the initial incision and the proximal end of the implant device prior to removal.

Time frame:
Group 1 (6-month): Assessments performed day 1 and day 183. Group 2 (12-month): Assessments performed day 1 and 364.
Reported as:
Number · number of participants
Number of Participants Who Experienced Implant Migration in at Least One of the Implanted Devices
number of participantsDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Number of Participants Who Experienced Implant Migration in at Least One of the Implanted Devices00

Adverse events

Collected over Group 1 (6-month implant group): Up to 8-months (Includes oral phase, implant phase, and follow up). Group 2 (12-month implant group): Up to 15-months (Includes oral phase, implant phase, and follow up).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DLP-114 Alpha-4 (6-months)0/14 (0%)0/14 (0%)10/14 (71.4%)
DLP-114 Alpha-7 (12-months)0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Most frequent serious events
Most frequent serious events
EventDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
Oedema PeripheralGeneral disorders0/141/14
Weight IncreaseInvestigations0/141/14
AscitesGastrointestinal disorders0/141/14
Cardiac Failure CongestiveCardiac disorders0/141/14
DyspnoeaRespiratory, thoracic and mediastinal disorders0/141/14
Most frequent other events
Showing 10 of 39
Most frequent other events
EventDLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)
InsomniaPsychiatric disorders1/143/14
ArthralgiaMusculoskeletal and connective tissue disorders3/140/14
Weight increasedInvestigations3/140/14
Back PainMusculoskeletal and connective tissue disorders2/140/14
Implant site painGeneral disorders2/142/14
SomnolenceNervous system disorders2/141/14
Injection site discomfortGeneral disorders0/142/14
Abdominal PainGastrointestinal disorders2/140/14
Increased appetiteMetabolism and nutrition disorders2/140/14
Implant site haemorrhageGeneral disorders1/140/14

Baseline characteristics

Represents the number of participants who completed the oral phase and enrolled in the implant phase.

Age, Categorical
Age, Categorical(Participants)DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)Total
<=18 years000
Between 18 and 65 years141428
>=65 years000
Age, Continuous
Age, Continuous(Years)DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)Total
Median54.5 (23 to 62)54.5 (28 to 64)54.5 (23 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)Total
Female347
Male111021
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)Total
Hispanic or Latino213
Not Hispanic or Latino121325
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DLP-114 Alpha-4 (6-months)DLP-114 Alpha-7 (12-months)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American91322
White516
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Collaborative Neuroscience Research
    Long Beach, California 90806, United States
  • Segal Trials
    Miami Lakes, Florida 33016, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Feb 2023, 22 months.

Results were first posted in Dec 2024, 1 year 10 months after primary completion.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 5, 2020
StartActual
Apr 1, 2021
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Results first posted
Dec 27, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04418466
Lead sponsor
Delpor, Inc.
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Apr 1, 2021
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Results posted
Dec 27, 2024
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion